As at April 12, 2024Show prices
SaskWorks Diversified (Class A - Series A) - 27.0355
SaskWorks Diversified (Class A - Series B) - 29.0139
SaskWorks Diversified (Class A - Series F) - 32.2043
SaskWorks Resources (Class R - Series A) - 24.7662
SaskWorks Resources (Class R - Series B) - 30.5720
SaskWorks Resources (Class R - Series F) - 26.5359
Brent Zettl, President and CEO, CanniMed Therapeutics Inc.(TSX:CMED) and Rob Duguid , Chief Investment Officer, PFM Capital Inc. joined Brady Fletcher, Managing Director, TSX Venture Exchange to open the market. CanniMed is a Canadian-based, international plant biopharmaceutical company with 15 years of pharmaceutical cannabis cultivation experience. The Company has a plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications. CanniMedTherapeutics Inc., will commence trading on Toronto Stock Exchange on December 29, 2016. For more information, please visit www.cannimed.ca
Please select the option that best describes you: